Cover Image

Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy

Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in melanoma pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Salzmann, Martin (Author) , Hess, Klaus (Author) , Uzun-Lang, Kristin (Author) , Enk, Alexander (Author) , Jordan, Berit (Author) , Hassel, Jessica C. (Author)
Format: Article (Journal)
Language:English
Published: October 2022
In: Strahlentherapie und Onkologie
Year: 2022, Volume: 198, Issue: 10, Pages: 884-891
ISSN:1439-099X
DOI:10.1007/s00066-022-01950-1
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1007/s00066-022-01950-1
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00066-022-01950-1
Get full text
Author Notes:Martin Salzmann, Klaus Hess, Kristin Lang, Alexander H. Enk, Berit Jordan, Jessica C. Hassel
Description
Summary:Whole-brain radiotherapy (WBRT) used to be standard of care for patients suffering from melanoma brain metastases (MBM) and may still be applicable in selected cases. Deterioration of neurocognitive function (NCF) is commonly seen during and after WBRT. Knowledge on long-term effects in melanoma patients is limited due to short survival rates. With the introduction of immune checkpoint inhibitors, patients may experience ongoing disease control, emphasizing the need for paying more attention to potential long-term adverse effects.
Item Description:Gesehen am 17.11.2022
Physical Description:Online Resource
ISSN:1439-099X
DOI:10.1007/s00066-022-01950-1

Similar Items